Prescription medicine
Anti-inhibitor coagulant complex Brand names: Feiba
Anti-inhibitor coagulant complex (Feiba) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
- Boxed warning
Check it at the source: the anti-inhibitor coagulant complex FDA label on DailyMed (effective November 27, 2025); every anti-inhibitor coagulant complex label on DailyMed.
Highlights of the record
FDA label of November 27, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
EMBOLIC and THROMBOTIC EVENTS Thromboembolic events have been reported during postmarketing surveillance following infusion of FEIBA, particularly following the administration of high doses and/or in patients with thrombotic risk factors. Monitor patients receiving FEIBA for signs and symptoms of thromboembolic events. WARNING: EMBOLIC and THROMBOTIC EVENTS See full prescribing information for complete boxed warning. Thromboembolic events have been reported during postmarketing surveillance, particularly following the administration of high doses and/or in patients with thrombotic risk factors. Monitor patients receiving FEIBA for signs and symptoms of thromboembolic events ( 5.1 , 6.2 ).
Used for
From the label: indications and usageFEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for: Control and prevention of bleeding episodes Perioperative management Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
Forms and strengths
Kit.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 1,102 through July 30, 2026
What is anti-inhibitor coagulant complex used for?
From the label: indications and usageFEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for: Control and prevention of bleeding episodes Perioperative management Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. FEIBA is not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to coagulation factor VIII or coagulation factor IX. FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for: Control and prevention of bleeding episodes. Perioperative management. […]
Source: FDA drug label (FEIBA), Takeda Pharmaceuticals America, Inc., effective November 27, 2025 (SPL set 752604e5-4ea2-44f4-83ed-1569373f6412), via openFDA; the full label on DailyMed
Is there a generic for anti-inhibitor coagulant complex (Feiba)?
No generic anti-inhibitor coagulant complex is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the anti-inhibitor coagulant complex label say about other medicines?
The anti-inhibitor coagulant complex label names 3 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Aminocaproic acid | drug interactions | DRUG INTERACTIONS Consider the possibility of thrombotic events when systemic antifibrinolytics such as tranexamic acid and aminocaproic acid are used. |
| Emicizumab | drug interactions | Clinical experience from an emicizumab clinical trial suggests that a potential drug interaction may exist with emicizumab when FEIBA was used as part of a treatment regimen for breakthrough bleeding 6 [see Warnings and Precautions (5.1) ]. |
| Tranexamic acid | drug interactions | DRUG INTERACTIONS Consider the possibility of thrombotic events when systemic antifibrinolytics such as tranexamic acid and aminocaproic acid are used. |
Check anti-inhibitor coagulant complex against other medicines
Source: FDA drug label (FEIBA), Takeda Pharmaceuticals America, Inc., effective November 27, 2025 (SPL set 752604e5-4ea2-44f4-83ed-1569373f6412), via openFDA; the full label on DailyMed
What do FAERS reports show for anti-inhibitor coagulant complex?
The FDA Adverse Event Reporting System holds 1,102 reports that list anti-inhibitor coagulant complex among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 151 are coded as a death and 225 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Anti-inhibitor coagulant complex side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other